Literature DB >> 7074894

Familial porphyria cutanea tarda: the pattern of porphyrins formed from porphobilinogen by hemolysates.

M A Alleman, J H Wilson, J W van den Berg, A Edixhoven-Bosdijk, L M van Gastel-Quist.   

Abstract

Porphyria cutanea tarda is thought to result from an inherited deficiency of uroporphyrinogen decarboxylase (EC 4.1.1.37) in some patients. Present methods for determining uroporphyrinogen decarboxylase activity are time consuming, so we examined the pattern of porphyrins formed from porphobilinogen by hemolysates as a possible marker for hereditary porphyria cutanea tarda. After the hemolysates are incubated with porphobilinogen, the porphyrins are converted to their methyl esters and examined by liquid chromatography, with fluorometric detection. The porphyrinic patients examined, and some of their relatives, showed a characteristic pattern of porphyrin production, with high uroporphyrin/coproporphyrin and (uroporphyrin + heptacarboxylic porphyrins)/coproporphyrin ratios, at least partly ascribable to increased uroporphyrinogen I synthetase (EC 4.2.1.8) activity in patients' hemolysates, and also to a relative deficiency of uroporphyrinogen decarboxylase. Examination of the pattern of porphyrins produced from porphobilinogen by hemolysates is a suitable technique for detecting asymptomatic individuals with porphyria cutanea tarda.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074894

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  2 in total

1.  The role of iron in experimental porphyria and porphyria cutanea tarda.

Authors:  P D Siersema; R P van Helvoirt; M I Cleton-Soeteman; W C de Bruijn; J H Wilson; H G van Eijk
Journal:  Biol Trace Elem Res       Date:  1992-10       Impact factor: 3.738

2.  The effects of chronic carbamazepine treatment of haem biosynthesis in man and rat.

Authors:  G M McGuire; G J Macphee; G G Thompson; B K Park; M R Moore; M J Brodie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.